Longitudinal changes in inflammatory biomarkers among patients with COVID‐19: A nationwide study in Iceland
- 29 July 2022
- journal article
- research article
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 66 (8) , 969-977
Abstract
Objectives All SARS-CoV-2-positive persons in Iceland were prospectively monitored and those who required outpatient evaluation or were admitted to hospital underwent protocolized evaluation that included a standardized panel of biomarkers. The aim was to describe longitudinal changes in inflammatory biomarkers throughout the infection period of patients with COVID-19 requiring different levels of care. Design Registry-based study. Setting Nationwide study in Iceland. Patients All individuals who tested positive for SARS-CoV-2 by real-time polymerase chain reaction (RT-PCR) from February 28 to December 31, 2020 in Iceland and had undergone blood tests between 5 days before and 21 days following onset of symptoms. Measurements and Main Results Data were collected from the electronic medical record system of Landspitali-The National University Hospital of Iceland. Data analyses were descriptive and the evolution of biomarkers was visualized using locally weighted scatterplot smoothing curves stratified by the worst clinical outcome experienced by the patient: outpatient evaluation only, hospitalization, and either intensive care unit (ICU) admission or death. Of 571 included patients, 310 (54.3%) only required outpatient evaluation or treatment, 202 (35.4%) were hospitalized, and 59 (10.3%) were either admitted to the ICU or died. An early and persistent separation of the mean lymphocyte count and plasma C-reactive protein (CRP) and ferritin levels was observed between the three outcome groups, which occurred prior to hospitalization for those who later were admitted to ICU or died. Lower lymphocyte count, and higher CRP and ferritin levels correlated with worse clinical outcomes. Patients who were either admitted to the ICU or died had sustained higher white blood cell and neutrophil counts, and elevated plasma levels of procalcitonin and D-dimer compared with the other groups. Conclusions Lymphocyte count and plasma CRP and ferritin levels might be suitable parameters to assess disease severity early during COVID-19 and may serve as predictors of worse outcome.Keywords
Funding Information
- Landspitali University Hospital
This publication has 18 references indexed in Scilit:
- Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in ChinaJournal of Allergy and Clinical Immunology, 2020
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysisClinica Chimica Acta, 2020
- Beating the odds with systematic individualized care: Nationwide prospective follow‐up of all patients with COVID‐19 in IcelandJournal of Internal Medicine, 2020
- Coagulation abnormalities and thrombosis in patients with COVID-19The Lancet Haematology, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Molecular immune pathogenesis and diagnosis of COVID-19Journal of Pharmaceutical Analysis, 2020
- Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and TransmissibilityClinical Infectious Diseases, 2020
- Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysisTravel Medicine and Infectious Disease, 2020
- IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in InfectionsPLOS Pathogens, 2016